Completed PHASE1 INTERVENTIONAL 2-arm NCT01776437

Study of BMN 673, a PARP Inhibitor, in Healthy Adult Male Volunteers

A Phase 1 Food Effect Study of BMN 673 Administered to Healthy Adult Male Volunteers

Sponsor: Pfizer

Interventions BMN 673

Updated 7 times since 2017 Last updated: Jul 26, 2017 Started: Feb 28, 2013 Primary completion: May 31, 2013 Completion: Jul 31, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01776437, this PHASE1 trial focuses on Human Volunteers and remains completed. Sponsored by Pfizer, it has been updated 7 times since 2013, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Sep 2017 — Jun 2018 [monthly]

Completed PHASE1

▶ Show 2 earlier versions

Feb 2017 — Sep 2017 [monthly]

Completed PHASE1
Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Feb 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Pfizer

Data source: Pfizer

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Evansville, United States